Medication info
Nexipra Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Nexipra Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg / 1 tablet
Manufacturer / importer
Kukje Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP × 2)
Approval status
Active

MFDS item code 201403997 · Approved 2014.08.27 · Insurance code 643703840

Summary

Main use
Treatment of gastric acid disorders (e.g., reflux); eradication therapy, ulcer treatment, and prevention of rebleeding; treatment of gastrointestinal disorders caused by anti-inflammatory drugs
Who uses it
Adults · Children
Adult dosage
Swallow this medicine with a liquid such as water. Do not chew or crush it. 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical trials longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: Dosage adjustment is not necessary. Use with caution because experience in patients with severe renal impairment is limited. Hepatic impairment: Dosage adjustment is not necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medicine. Elderly patients: Dosage adjustment is not necessary.
Children's dosage
Adolescents 12 years of age and older — Gastroesophageal reflux disease (GERD), treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents 12 years of age and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Adolescents 12 years of age and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. Pediatric patients under 12 years of age: There is no experience with administration of this medicine to pediatric patients under 12 years of age.

Ingredients

Manufacturer
Kukje Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastric acid disorders (e.g., reflux); eradication therapy, ulcer treatment, and prevention of rebleeding; treatment of gastrointestinal disorders caused by anti-inflammatory drugs

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcers
View approved original text

This medication is used as maintenance therapy to treat gastroesophageal reflux disease and to prevent relapse of erosive reflux esophagitis. It is also effective for the treatment and prevention of recurrence of duodenal ulcers and gastric ulcers when used in combination with antibiotics for the eradication of Helicobacter pylori. It is used for alleviating upper gastrointestinal symptoms and treating gastric ulcers, as well as preventing gastric and duodenal ulcers. It may assist in the treatment of Zollinger-Ellison syndrome and is used as maintenance therapy after intravenous induction for the prevention of re-bleeding from gastric or duodenal ulcers. Overall, this drug is used for treating various gastrointestinal disorders and preventing recurrence.

Dosage and Administration

Adult dosage

Swallow this medicine with a liquid such as water. Do not chew or crush it. 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical trials longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should thereafter be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following intravenous induction to prevent rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction to prevent rebleeding from gastric or duodenal ulcers. Renal impairment: Dosage adjustment is not necessary. Use with caution because experience in patients with severe renal impairment is limited. Hepatic impairment: Dosage adjustment is not necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medicine. Elderly patients: Dosage adjustment is not necessary.

Children's dosage

Adolescents 12 years of age and older — Gastroesophageal reflux disease (GERD), treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents 12 years of age and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Adolescents 12 years of age and older — Gastroesophageal reflux disease (GERD), symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. Pediatric patients under 12 years of age: There is no experience with administration of this medicine to pediatric patients under 12 years of age.

Precautions

This medication should not be used in patients with a history of allergy or hypersensitivity to specific components. In particular, patients who are hypersensitive to penicillin or macrolide antibiotics, those who are on specific cardiovascular medications, nursing mothers, and patients with a history of myocardial infarction should avoid using this medication. Patients with an allergy to Yellow No. 4 (Tartrazine) should use it cautiously. Various adverse reactions may occur with this drug, including headache, abdominal pain, diarrhea, rash, myalgia, and liver function abnormalities among others. Although rare, serious skin reactions, blood abnormalities, and hypomagnesemia can occur, necessitating immediate consultation with a physician if symptoms appear. Regular monitoring is required during long-term use, and any changes in symptoms should be discussed with a doctor. This medication may interact with other drugs, so it’s important to inform healthcare providers of any other medications being taken. Caution is necessary when used in conjunction with antiviral agents, antibiotics, anticoagulants, and others. The safety of this drug during pregnancy has not been fully established, so caution is advised during use, and it is recommended not to be taken while breastfeeding. In case of overdose, there is no specific antidote, so treatment should be symptomatic, and it should be kept out of reach of children. It is also advisable not to transfer the medication to another container, and to maintain it in the original packaging.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, bilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsion, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, anorexia, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorder, tremor, visual field defect, dysmenorrhea, menstrual disorder, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papulovesicular rash, angioedema, otitis media, olfactory disturbance, loss of taste, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, voiding frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal pigmentation, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering. The storage temperature should be maintained between 1°C and 30°C at room temperature. This will help keep the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP × 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.